Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICADNASDAQ:MBOTNASDAQ:OBIONASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICADiCAD$3.88+1.0%$2.99$1.18▼$4.01$106.59M1.35720,281 shs400,114 shsMBOTMicrobot Medical$2.67+5.1%$2.24$0.82▼$3.38$97.13M1.153.73 million shs941,753 shsOBIOOrchestra BioMed$3.16+10.9%$2.94$2.37▼$8.87$121.07M0.67271,457 shs314,747 shsPYPDPolyPid$2.95+5.4%$2.70$2.30▼$4.50$30.06M1.2517,821 shs143,824 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICADiCAD0.00%+2.68%+9.43%+62.29%+164.14%MBOTMicrobot Medical0.00%-3.01%+7.95%+89.71%+158.00%OBIOOrchestra BioMed0.00%+4.78%+4.01%-30.49%-58.87%PYPDPolyPid0.00%+2.20%+1.79%-4.05%-36.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICADiCAD0.4251 of 5 stars0.03.00.00.02.60.80.0MBOTMicrobot Medical2.0804 of 5 stars3.52.00.00.03.50.00.6OBIOOrchestra BioMed3.1508 of 5 stars4.64.00.00.02.40.80.0PYPDPolyPid2.1344 of 5 stars3.63.00.00.01.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICADiCAD 2.00HoldN/AN/AMBOTMicrobot Medical 3.00Buy$9.00237.08% UpsideOBIOOrchestra BioMed 3.20Buy$14.20349.37% UpsidePYPDPolyPid 3.25Buy$11.33284.18% UpsideCurrent Analyst Ratings BreakdownLatest PYPD, OBIO, ICAD, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.005/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/17/2025ICADiCADLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/16/2025ICADiCADBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/16/2025ICADiCADCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/10/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICADiCAD$19.53M5.46N/AN/A$1.27 per share3.06MBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AOBIOOrchestra BioMed$2.89M41.95N/AN/A$1.90 per share1.66PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICADiCAD-$4.85M-$0.19N/A∞N/A-17.81%-15.65%-12.52%8/11/2025 (Estimated)MBOTMicrobot Medical-$10.74M-$0.65N/AN/AN/AN/A-218.30%-158.17%8/13/2025 (Estimated)OBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/APYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-624.10%-129.28%8/13/2025 (Estimated)Latest PYPD, OBIO, ICAD, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/13/2025Q1 2025ICADiCAD-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 million3/26/2025Q4 2024MBOTMicrobot Medical-$0.18-$0.20-$0.02-$0.20N/AN/A3/19/2025Q4 2024ICADiCAD-$0.0525-$0.03+$0.0225-$0.03$4.72 million$5.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICADiCADN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICADiCADN/A4.023.91MBOTMicrobot MedicalN/A3.643.64OBIOOrchestra BioMedN/A4.234.21PYPDPolyPid0.081.311.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICADiCAD24.61%MBOTMicrobot Medical16.30%OBIOOrchestra BioMed53.55%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipICADiCAD10.29%MBOTMicrobot Medical4.74%OBIOOrchestra BioMed8.10%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICADiCAD14027.47 million23.81 millionOptionableMBOTMicrobot Medical2036.38 million25.64 millionOptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataPYPD, OBIO, ICAD, and MBOT HeadlinesRecent News About These CompaniesPolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short InterestMay 31 at 2:41 AM | americanbankingnews.comPolyPid at Lytham Partners: Strategic Advances and Financial StabilityMay 30 at 6:22 PM | investing.comPESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data ReadoutMay 30 at 10:12 AM | globenewswire.comPolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025May 20, 2025 | globenewswire.comPolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMay 16, 2025 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comPolyPid Ltd. (PYPD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPolyPid Completes Enrollment in Phase 3 Trial of D-PLEX100May 14, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comA Look Ahead: PolyPid's Earnings ForecastMay 13, 2025 | benzinga.comPolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025April 29, 2025 | globenewswire.comPolyPid to Participate in The Citizens Life Sciences ConferenceApril 22, 2025 | globenewswire.comPolyPid management to meet with OppenheimerApril 17, 2025 | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on PolyPid (PYPD)March 25, 2025 | markets.businessinsider.comPolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100March 12, 2025 | markets.businessinsider.comCraig-Hallum Remains a Buy on PolyPid (PYPD)March 12, 2025 | markets.businessinsider.comPolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection PreventionMarch 11, 2025 | tipranks.comPolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsMarch 11, 2025 | globenewswire.comPolyPid to Participate in the 37th Annual ROTH ConferenceMarch 3, 2025 | globenewswire.comPolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYPD, OBIO, ICAD, and MBOT Company DescriptionsiCAD NASDAQ:ICAD$3.88 +0.04 (+1.04%) Closing price 04:00 PM EasternExtended Trading$3.84 -0.03 (-0.90%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.Microbot Medical NASDAQ:MBOT$2.67 +0.13 (+5.12%) Closing price 04:00 PM EasternExtended Trading$2.68 +0.02 (+0.56%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Orchestra BioMed NASDAQ:OBIO$3.16 +0.31 (+10.88%) Closing price 04:00 PM EasternExtended Trading$3.12 -0.04 (-1.30%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.PolyPid NASDAQ:PYPD$2.95 +0.15 (+5.36%) Closing price 04:00 PM EasternExtended Trading$3.05 +0.10 (+3.39%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
